Allie Strickler

Articles

Expert Highlights Efficacy of KTE-C19 CAR T-Cell Therapy in Non-Hodgkin Lymphoma

January 6th 2017

KTE-C19, an investigational CAR T-cell therapy, recently demonstrated positive results for patients with chemorefractory aggressive non-Hodgkin lymphoma.

Reduced-Dose Radiation Effective in HPV-Associated Oropharynx Cancers

January 6th 2017

Induction chemotherapy followed by reduced-dose radiation and weekly cetuximab demonstrated improved swallowing and nutritional status as well as an excellent complete clinical response for patients with HPV-associated oropharyngeal squamous cell carcinoma.

R-CHOP Remains Frontline Standard in DLBCL, Says Expert

January 5th 2017

The regimen of rituximab plus CHOP chemotherapy has been the standard of care for patients with previously untreated diffuse large B-cell lymphoma for several years, and it appears it will remain that way for now, despite recent research to find novel alternatives.

Expert Discusses "Sequential Triple-T" Trials in CLL

January 4th 2017

In the treatment paradigm of chronic lymphocytic leukemia, anti-CD20 antibodies such as obinutuzumab, and other targeted agents like ibrutinib, have shown promising efficacy and tolerability when compared with standard chemoimmunotherapy.

CT-Planned, High-Dose-Rate Brachytherapy Effective in Cervical Cancer

December 28th 2016

The use of CT-planned high-dose-rate intracavitary brachytherapy demonstrated excellent local control and survival for patients with stage I/II cervical carcinoma, according to the results of a recent study published in Gynecologic Oncology.

Expedited Surgery Increases Mortality Risk in Endometrial Cancer

December 27th 2016

Patients with endometrial cancer who receive surgery in the first 2 weeks after diagnosis have worse survival outcomes, according to a study recently reported in the American Journal of Obstetrics and Gynecology.

Study Links NSAIDs to Increased Mortality in Endometrial Cancer

December 27th 2016

An association was found between the use of nonsteroidal anti-inflammatory drugs and endometrial cancer risk.

Distinct, Aggressive Subgroup of ACC Identified With Activating NOTCH1 Mutations

December 23rd 2016

NOTCH1 mutations have been found to define an aggressive subgroup of patients with adenoid cystic carcinomas, with a corresponding pattern of metastatic spread.

Concomitant Chemo Regimens Most Effective for Locally Advanced Nasopharyngeal Carcinoma

December 22nd 2016

The addition of chemotherapy, either adjuvant or induction, to concomitant chemoradiotherapy achieved a significantly high survival benefit for patients with locally advanced nasopharyngeal carcinoma.

Entospletinib Shows Modest Activity in Mantle Cell Lymphoma

December 20th 2016

Entospletinib was well tolerated and demonstrated modest activity in patients with relapsed or refractory mantle cell lymphoma.

Expert Discusses Recent Progress in NET Management

December 19th 2016

Significant progress has been made in recent years in understanding the biology and treatment of neuroendocrine tumors.

Expert Praises Predictive Role of Radiomics in Sarcoma

December 15th 2016

Several challenges remain in the treatment landscape of soft tissue sarcoma, a disease whose diagnosis can range from one that is quite indolent for patients, to a more life-threatening, metastatic, aggressive cancer.

Expert Says Biomarkers Top Priority for Immunotherapy Progress in Ovarian Cancer

December 13th 2016

Although randomized phase III clinical trials often lead to groundbreaking drug approvals and offer novel therapeutic regimens, Maurie Markman, MD, insists that the search for validated, actionable biomarkers is more important than initiation of new studies.

Frontline Pembrolizumab Shows Superior Health-Related QoL in NSCLC

December 7th 2016

Patients with non–small cell lung cancer treated in the pembrolizumab arm of the KEYNOTE-024 trial experienced improved quality of life compared with patients who were treated with standard chemotherapy.

Osimertinib Beats Chemo in Second-Line T790M-Mutant NSCLC

December 7th 2016

Osimertinib (Tagrisso) reduced the risk of disease progression by 70% compared with a chemotherapy doublet in patients with EGFR T790M-mutant non–small cell lung cancer (NSCLC) who progressed after first-line targeted therapy.

Immunotherapy Rapidly Redefining Treatment in Bladder Cancer

December 6th 2016

Daniel P. Petrylak, MD, sheds light on the emerging roles of both immunotherapy and targeted agents in the treatment of patients with bladder cancer.

Expert Highlights Importance of Novel Findings With Tobacco Cessation Practices

December 5th 2016

Douglas Arenberg, MD, discusses preliminary findings of a screening study, and the critical importance of maintaining quality tobacco cessation practices in healthcare clinics.

Expert Assesses Rapidly Expanding Therapeutic Options in RCC

December 1st 2016

The treatment landscape of renal cell carcinoma is changing at a remarkably fast pace.

Levine Sheds Light on Precision Medicine in Gynecologic Malignancies

November 28th 2016

Significant progress is being made in the treatment of gynecologic malignancies, especially in ovarian cancer, according to Douglas A. Levine, MD.

Expert Discusses the Future of Circulating Biomarkers in Prostate Cancer

November 23rd 2016

Biomarkers play a key role in the optimization of treatments for patients with prostate cancer. According to Mark Stein, MD, they can even serve as clinical endpoints in trials.